Dr. Lal PathLabs Inkomsten in het verleden

Verleden criteriumcontroles 6/6

Dr. Lal PathLabs is de winst gegroeid met een gemiddeld jaarlijks percentage van 7.8%, terwijl de Healthcare industrie de winst jaarlijks groeide met 29.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12.4% per jaar. Het rendement op eigen vermogen van Dr. Lal PathLabs is 20.5%, en het heeft een nettomarge van 16.7%.

Belangrijke informatie

7.8%

Groei van de winst

7.6%

Groei van de winst per aandeel

Healthcare Groei van de industrie	29.4%
Inkomstengroei	12.4%
Rendement op eigen vermogen	20.5%
Nettomarge	16.7%
Volgende winstupdate	23 Oct 2024

Recente prestatie-updates uit het verleden

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21

Recent updates

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25

Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?

Apr 28

Opbrengsten en kosten

Hoe Dr. Lal PathLabs geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:LALPATHLAB Opbrengsten, kosten en inkomsten (INR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	22,875	3,815	4,227	0
31 Mar 24	22,266	3,577	4,135	0
31 Dec 23	21,722	3,298	3,856	0
30 Sep 23	21,227	3,013	3,772	0
30 Jun 23	20,552	2,638	2,869	0
31 Mar 23	20,169	2,388	3,577	0
31 Dec 22	20,114	2,435	3,349	0
30 Sep 22	20,189	2,480	3,299	0
30 Jun 22	19,835	2,713	3,255	0
31 Mar 22	20,874	3,448	3,480	0
31 Dec 21	20,329	3,669	3,303	0
30 Sep 21	19,884	4,041	3,264	0
30 Jun 21	19,219	3,944	3,126	0
31 Mar 21	15,813	2,916	2,501	0
31 Dec 20	14,520	2,407	2,343	0
30 Sep 20	13,275	2,003	2,160	0
30 Jun 20	12,612	1,955	2,079	0
31 Mar 20	13,304	2,259	2,222	0
31 Dec 19	13,298	2,405	2,540	0
30 Sep 19	12,944	2,322	2,493	0
30 Jun 19	12,463	2,086	2,412	0
31 Mar 19	12,034	1,992	2,341	0
31 Dec 18	11,691	1,923	2,294	0
30 Sep 18	11,393	1,825	2,238	0
30 Jun 18	10,999	1,761	2,173	0
31 Mar 18	10,569	1,707	2,102	0
31 Dec 17	10,100	1,617	898	0
30 Sep 17	9,548	1,565	808	0
30 Jun 17	9,389	1,586	752	0
31 Mar 17	9,124	1,546	1,694	0
31 Dec 16	8,902	1,576	700	0
30 Sep 16	8,713	1,876	676	0
30 Jun 16	8,249	1,413	625	0
31 Mar 16	7,913	1,322	580	0
31 Dec 15	7,654	1,201	2,152	11
31 Mar 15	6,596	908	497	0
31 Mar 14	5,579	763	1,755	10

Kwaliteitswinsten: LALPATHLAB heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (16.7%) LALPATHLAB } zijn hoger dan vorig jaar (12.8%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van LALPATHLAB is de afgelopen 5 jaar met 7.8% per jaar gegroeid.

Versnelling van de groei: De winstgroei van LALPATHLAB over het afgelopen jaar ( 44.6% ) overtreft het 5-jarig gemiddelde ( 7.8% per jaar).

Winst versus industrie: De winstgroei LALPATHLAB over het afgelopen jaar ( 44.6% ) overtrof de Healthcare -sector 30.6%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 20.5% ) van LALPATHLAB wordt als hoog beschouwd.

Dr. Lal PathLabs Inkomsten in het verleden

Verleden criteriumcontroles 6/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

Recent updates

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

MD & Director recently sold ₹28m worth of stock

Price target increased by 12% to ₹2,924

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

MD & Director recently sold ₹41m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock